JP2021532109A5 - - Google Patents

Info

Publication number
JP2021532109A5
JP2021532109A5 JP2021503147A JP2021503147A JP2021532109A5 JP 2021532109 A5 JP2021532109 A5 JP 2021532109A5 JP 2021503147 A JP2021503147 A JP 2021503147A JP 2021503147 A JP2021503147 A JP 2021503147A JP 2021532109 A5 JP2021532109 A5 JP 2021532109A5
Authority
JP
Japan
Prior art keywords
membered
alkyl
cycloalkyl
aryl
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021503147A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021532109A (ja
JP7386841B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/043123 external-priority patent/WO2020023560A1/en
Publication of JP2021532109A publication Critical patent/JP2021532109A/ja
Publication of JP2021532109A5 publication Critical patent/JP2021532109A5/ja
Application granted granted Critical
Publication of JP7386841B2 publication Critical patent/JP7386841B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021503147A 2018-07-24 2019-07-23 イソキノリン化合物及びその使用 Active JP7386841B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2018/096780 2018-07-24
CN2018096780 2018-07-24
PCT/US2019/043123 WO2020023560A1 (en) 2018-07-24 2019-07-23 Isoquinoline compounds and uses thereof

Publications (3)

Publication Number Publication Date
JP2021532109A JP2021532109A (ja) 2021-11-25
JP2021532109A5 true JP2021532109A5 (enExample) 2022-07-22
JP7386841B2 JP7386841B2 (ja) 2023-11-27

Family

ID=67551418

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021503147A Active JP7386841B2 (ja) 2018-07-24 2019-07-23 イソキノリン化合物及びその使用

Country Status (6)

Country Link
US (1) US12378249B2 (enExample)
EP (1) EP3826722B1 (enExample)
JP (1) JP7386841B2 (enExample)
CN (1) CN112601584A (enExample)
TW (1) TW202019905A (enExample)
WO (1) WO2020023560A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019010302A (es) 2017-03-30 2019-11-21 Hoffmann La Roche Isoquinolinas como inhibidores de hpk1.
JP7386841B2 (ja) 2018-07-24 2023-11-27 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト イソキノリン化合物及びその使用
WO2020069402A1 (en) * 2018-09-30 2020-04-02 Genentech, Inc. Cinnoline compounds and for the treatment of hpk1-dependent disorders such as cancer
TW202024053A (zh) 2018-10-02 2020-07-01 美商建南德克公司 異喹啉化合物及其用途
TW202023558A (zh) 2018-10-03 2020-07-01 美商建南德克公司 8-胺基異喹啉化合物及其用途
EP4371987B9 (en) 2018-10-31 2025-11-26 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds as hpk1 inhibitors
EP3873608A1 (en) 2018-10-31 2021-09-08 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
US11453681B2 (en) 2019-05-23 2022-09-27 Gilead Sciences, Inc. Substituted eneoxindoles and uses thereof
EP4090663A1 (en) * 2020-01-15 2022-11-23 Blueprint Medicines Corporation Map4k1 inhibitors
CN116456985A (zh) * 2020-09-23 2023-07-18 深圳市原力生命科学有限公司 作为hpk1调节剂的嘧啶及吡啶衍生物和其使用方法
EP4240361A4 (en) * 2020-11-09 2024-09-25 Merck Sharp & Dohme LLC INHIBITORS, OF THE 7-AZOLE SUBSTITUTED 2-AMINOQUINAZOLINE TYPE, OF HPK1
CN114516857A (zh) * 2020-11-20 2022-05-20 深圳智药信息科技有限公司 Hpk1抑制剂及其用途
US20240182465A1 (en) * 2021-03-03 2024-06-06 Genfleet Therapeutics (Shanghai) Inc. Fused ring substituted six-membered heterocyclic compound, preparation method therefor and use thereof
WO2023001794A1 (en) 2021-07-20 2023-01-26 Astrazeneca Ab Substituted pyrazine-2-carboxamides as hpk1 inhibitors for the treatment of cancer
US20250084078A1 (en) * 2022-01-04 2025-03-13 Genfleft Therapeutics (Shanghai) Inc. Fused ring-substituted six-membered heterocyclic compound, and preparation method therefor and use thereof
CN116672450A (zh) * 2022-02-23 2023-09-01 智宠制药(北京)有限公司 Hpk1抑制剂在治疗干扰素相关疾病中的应用
EP4554680A1 (en) 2022-07-15 2025-05-21 Arcus Biosciences, Inc. Inhibitors of hpk1 and methods of use thereof
CN119790047A (zh) * 2022-09-22 2025-04-08 北京望实智慧科技有限公司 Hpk1抑制剂、制备方法及其用途
WO2025029995A1 (en) * 2023-08-01 2025-02-06 Arvinas Operations, Inc. Hpk1 targeting compounds and uses thereof
CN117229202B (zh) * 2023-11-15 2024-01-26 苏州美诺医药科技有限公司 一种brd9靶向降解化合物的中间体的制备方法
WO2026035878A1 (en) * 2024-08-07 2026-02-12 Nimbus Saturn, Inc. Hpk1 inhibitor formulations and methods of making the same
WO2026035872A1 (en) * 2024-08-07 2026-02-12 Nimbus Saturn, Inc. Hpk1 inhibitor formulations and methods of making the same

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
DE3034001A1 (de) 1980-09-10 1982-04-22 Hoechst Ag, 6000 Frankfurt Isochinolinderivate, verfahren zu ihrer hersellung, sie enthaltende pharmazeutische zubereitungen und ihre verwendung
PL176081B1 (pl) 1995-06-06 1999-04-30 Politechnika Warszawska Sposób wytwarzania 3-aminoizochinoliny i jej N-mono oraz N,N-dipodstawionych pochodnych
WO2000071511A2 (en) 1999-05-24 2000-11-30 Cor Therapeutics, Inc. INHIBITORS OF FACTOR Xa
US7199149B2 (en) 2003-10-01 2007-04-03 Bristol Myers Squibb Company Monocyclic and bicyclic lactams as factor Xa inhibitors
JP2007008816A (ja) 2003-10-15 2007-01-18 Ube Ind Ltd 新規イソキノリン誘導体
EP1655295A1 (en) 2004-11-03 2006-05-10 Schering Aktiengesellschaft Anthranilamide pyridinureas as VEGF receptor kinase inhibitors
EP1657241A1 (en) 2004-11-03 2006-05-17 Schering Aktiengesellschaft Novel anthranilamide pyridinureas as VEGF receptor kinase inhibitors
US20060156485A1 (en) 2005-01-14 2006-07-20 The Procter & Gamble Company Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof
EP1899322B1 (en) 2005-06-28 2009-09-02 Sanofi-Aventis Isoquinoline derivatives as inhibitors of rho-kinase
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
DOP2006000233A (es) 2005-10-28 2007-06-15 Lilly Co Eli Inhibidores de cinasa
US7572809B2 (en) 2005-12-19 2009-08-11 Hoffmann-La Roche Inc. Isoquinoline aminopyrazole derivatives
AU2007207743B2 (en) 2006-01-18 2010-07-08 Amgen Inc. Thiazole compounds as protein kinase B (PKB) inhibitors
WO2007125405A2 (en) * 2006-05-01 2007-11-08 Pfizer Products Inc. Substituted 2-amino-fused heterocyclic compounds
AU2007338410B2 (en) 2006-12-27 2012-08-16 Sanofi-Aventis Cycloalkylamine substituted isoquinoline derivatives
EP1975166A1 (en) 2007-03-30 2008-10-01 Bayer Schering Pharma AG Synthesis of anthranilamides
EP2008658A1 (en) 2007-06-28 2008-12-31 Bayer Schering Pharma Aktiengesellschaft Synergistic combination of anthranilamide pyridinureas and benzamide derivatives
CN101821279A (zh) 2007-08-15 2010-09-01 赛特凯恩蒂克公司 某些化学个体、组合物和方法
GB0803018D0 (en) 2008-02-19 2008-03-26 Cancer Rec Tech Ltd Therapeutic compounds and their use
US8309577B2 (en) 2008-04-23 2012-11-13 Bristol-Myers Squibb Company Quinuclidine compounds as α-7 nicotinic acetylcholine receptor ligands
US7863291B2 (en) 2008-04-23 2011-01-04 Bristol-Myers Squibb Company Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands
GB0812969D0 (en) 2008-07-15 2008-08-20 Sentinel Oncology Ltd Pharmaceutical compounds
WO2010098788A2 (en) 2008-08-25 2010-09-02 Amplimmune, Inc. Pd-i antagonists and methods for treating infectious disease
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
EP2504028A4 (en) 2009-11-24 2014-04-09 Amplimmune Inc SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
EP3279215B1 (en) 2009-11-24 2020-02-12 MedImmune Limited Targeted binding agents against b7-h1
JP5793766B2 (ja) 2009-12-16 2015-10-14 ファイザー・インク 抗菌剤として有用なn−結合型ヒドロキサム酸誘導体
CN102791687B (zh) 2009-12-18 2015-02-11 北京凯因科技股份有限公司 C型肝炎病毒复制的新型抑制剂
EP2552893B1 (en) 2010-03-31 2014-10-29 Actelion Pharmaceuticals Ltd. Antibacterial isoquinolin-3-ylurea derivatives
CN103189377B (zh) 2010-10-29 2015-02-25 辉瑞大药厂 N1/n2-内酰胺乙酰辅酶a羧化酶抑制剂
CA2817460A1 (en) 2010-12-17 2012-06-21 F. Hoffmann-La Roche Ag Substituted 6,6-fused nitrogenous heterocyclic compounds and uses thereof
WO2012137099A1 (en) 2011-04-08 2012-10-11 Pfizer Inc. Imidazole, pyrazole, and triazole derivatives useful as antibacterial agents
JP2014523880A (ja) 2011-06-23 2014-09-18 ヴィアメット ファーマスーティカルズ,インコーポレイテッド 金属酵素化合物
WO2013003315A2 (en) 2011-06-26 2013-01-03 President And Fellows Of Harvard College Methods for preparing isoquinolines
WO2013169793A2 (en) 2012-05-09 2013-11-14 Ipierian, Inc. Methods and compositions for tdp-43 proteinopathies
CA2882750A1 (en) 2012-08-27 2014-03-06 Jim Blake Serine/threonine kinase inhibitors for the treatment of hyperproliferative|diseases
GB201216018D0 (en) * 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Pharmacologically active compounds
CA2883386A1 (en) 2012-09-14 2014-03-20 Eternity Bioscience Inc. Aminoisoquinoline derivatives as protein kinase inhibitors
WO2014123900A1 (en) 2013-02-05 2014-08-14 Sirenas Marine Discovery Anti-cancer and anti-hiv compounds
JP6397010B2 (ja) 2013-07-03 2018-09-26 カリオファーム セラピューティクス,インコーポレイテッド 置換されたベンゾフラニル及びベンゾオキサゾリル化合物並びにその使用
WO2016014674A1 (en) 2014-07-22 2016-01-28 University Of Maryland, College Park Linked diaryl compounds with anticancer properties and methods of using the same
GB201416754D0 (en) 2014-09-23 2014-11-05 Mission Therapeutics Ltd Novel compounds
RS61919B1 (sr) * 2015-06-25 2021-06-30 Univ Health Network Inhibitori hpk1 i postupci za njihovo korišćenje
AU2016340798A1 (en) 2015-10-20 2018-04-26 Axovant Sciences Gmbh Aminoisoxazoline compounds as agonists of alpha7-nicotinic acetylcholine receptors
BR112017002594A2 (pt) 2015-12-17 2017-12-19 Gilead Sciences Inc compostos inibidores de cinase de ligação de tank
CN107163022B (zh) 2016-03-07 2021-07-16 上海如絮生物科技有限公司 一种异喹啉类化合物、其中间体、制备方法和应用
US10407421B2 (en) 2016-03-07 2019-09-10 Merck Sharp & Dohme Corp Bicyclic aryl monobactam compounds and methods of use thereof for the treatment of bacterial infections
GB201604647D0 (en) 2016-03-18 2016-05-04 Mission Therapeutics Ltd Novel compounds
CN107266421B (zh) 2016-04-08 2020-12-04 正大天晴药业集团股份有限公司 取代的苯并咪唑类衍生物
AR108325A1 (es) 2016-04-27 2018-08-08 Samumed Llc Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
AR108326A1 (es) 2016-04-27 2018-08-08 Samumed Llc Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
US10280164B2 (en) * 2016-09-09 2019-05-07 Incyte Corporation Pyrazolopyridone compounds and uses thereof
AR109596A1 (es) * 2016-09-09 2018-12-26 Incyte Corp Compuestos pirazolopiridina y sus usos
TWI771327B (zh) 2016-10-05 2022-07-21 英商使命醫療公司 新穎化合物
US11180482B2 (en) * 2016-11-30 2021-11-23 Ariad Pharmaceuticals, Inc. Anilinopyrimidines as haematopoietic progenitor kinase 1 (HPK1) inhibitors
WO2018119263A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds derivatives as pd-l1 internalization inducers
MX389798B (es) 2017-01-20 2025-03-20 Arcus Biosciences Inc Azolopirimidina para el tratamiento de trastornos relacionados con el cáncer.
MX2019010302A (es) * 2017-03-30 2019-11-21 Hoffmann La Roche Isoquinolinas como inhibidores de hpk1.
JP6453507B2 (ja) 2017-03-30 2019-01-16 アムジエン・インコーポレーテツド Mcl−1タンパク質を阻害する化合物
AR111307A1 (es) 2017-03-30 2019-06-26 Takeda Pharmaceuticals Co Derivados de 1’,2’-dihidroespiro[ciclohexan-1,3’-indol] o 1’,2’-dihidroespiro[ciclohexan-1,3’-pirrolo[3,2-b]piridina] como inhibidores de hexakisfosfato quinasa
CN110831593A (zh) 2017-06-14 2020-02-21 特维娜有限公司 用于调节s1p1活性的化合物及其使用方法
US10604514B2 (en) 2017-10-19 2020-03-31 Samumed, Llc 6-(5-membered heteroaryl)isoquinolin-3-yl carboxamides and preparation and use thereof
US10653688B2 (en) 2017-10-27 2020-05-19 Samumed, Llc 6-(6-membered heteroaryl and aryl)isoquinolin-3-yl carboxamides and preparation and use thereof
US20210009541A1 (en) 2018-02-12 2021-01-14 Bayer Aktiengesellschaft Fungicidal oxadiazoles
JP7386841B2 (ja) 2018-07-24 2023-11-27 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト イソキノリン化合物及びその使用
TW202024053A (zh) 2018-10-02 2020-07-01 美商建南德克公司 異喹啉化合物及其用途
TW202023558A (zh) 2018-10-03 2020-07-01 美商建南德克公司 8-胺基異喹啉化合物及其用途

Similar Documents

Publication Publication Date Title
JP2021531311A5 (enExample)
JP2022516469A5 (enExample)
JP2022544714A5 (enExample)
JP2024507131A5 (enExample)
JP2020007311A5 (enExample)
JP2021534108A5 (enExample)
JP2012526728A5 (enExample)
JP2022515197A5 (enExample)
JP2018528942A5 (enExample)
JP2015511638A5 (enExample)
JP2019510798A5 (enExample)
CA2972014A1 (en) Fused pyrimidine compounds for the treatment of hiv
JP2013532652A5 (enExample)
RU2010111551A (ru) Замещенные индольные производные и способы их применения
HRP20230909T1 (hr) Spojevi inhibitori rip1 i postupci za njihovo dobivanje i upotrebu
JP2009543802A5 (enExample)
RU2010111550A (ru) 2,3-замещенные индольные производные для лечения вирусных инфекций
JP2021534097A5 (enExample)
JP2016509047A5 (enExample)
JP2019500387A5 (enExample)
JP2021502387A5 (enExample)
RU2008112691A (ru) Азотсодержащее гетероциклическое соединение и его фармацевтическое применение
JP2021535112A5 (enExample)
WO2018075959A4 (en) Methods using hdac11 inhibitors
JP2021518400A5 (enExample)